The deal with BlissBio is the latest in a cascade of multi-million- and billion-dollar acquisitions and collaborations centered on antibody-drug conjugates.
https://www.pharmalive.com/wp-content/uploads/2023/05/medical-lab-medical-research.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-05-09 09:07:152023-05-09 09:08:27Eisai pays up to $2B for ADC bearing its Halaven as payload
